New Gene Therapy Manufacturing Plant Opens In Maryland

Precigen, Inc., a clinical stage biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, announced on April 26 the official opening of its new manufacturing facility.
The company, a wholly-owned subsidiary of Intrexon Corp., commenced the build-out of the nearly 5,000 square foot manufacturing facility in 2018 to support gene therapy manufacturing. The new facility adds to Precigen's existing footprint in Germantown, Md., which supports more than 95 employees. The good manufacturing practices facility was designed with agility and control in mind, focusing on rapid manufacturing and the ability to scale production appropriately to meet early stage clinical trial needs.
Precigen needs to be agile and cost-conscious in our early-stage clinical manufacturing. In today's drug development environment, it's important to reduce a myriad of risks that can impact manufacturing such as technology transfer risks when outsourcing to contract manufacturing organizations as well as process and timing risks, said Helen Sabzevari, President of Precigen,Dr.  "This facility puts Precigen in control of our gene therapy manufacturing needs.